Prognostic role of inflammatory biomarkers from peripheral blood and clinical factors in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with radium-223 (Ra-223) (BIO-Ra-223 study).

被引：0
|
作者：
Rebuzzi, Sara Elena
Bauckneht, Matteo
Signori, Alessio
Frantellizzi, Viviana
Rizzini, Elisa Lodi
Mascia, Manlio
Lavelli, Valentina
Stazza, Maria Lina
Licari, Maria
Donegani, Maria Isabella
Ponzano, Marta
Cavallini, Letizia
Laghi, Viola
Cindolo, Luca
Costa, Renato Patrizio
Spanu, Angela
Rubini, Giuseppe
Monari, Fabio
De Vincentis, Giuseppe
Fornarini, Giuseppe
机构：
[1] Univ Genoa, Med Oncol Unit 1, IRCCS Osped Policlin San Martino, Dept Internal Med & Med Specialties DiMI, Genoa, Italy
[2] IRCCS Osped Policlin San Martino, Nucl Med Unit, Genoa, Italy
[3] Sapienza Univ Rome, Dept Mol Med, Rome, Italy
[4] IRCCS Azienda Osped Univ Bologna, Radiat Oncol, Bologna, Italy
[5] Spirito Santo Hosp, Nucl Med Unit, Pescara, Italy
[6] Univ Bari Aldo Moro, Dept Nucl Med, Bari, Italy
[7] Univ Sassari, Dept Med Surg & Expt Sci, Nucl Med Unit, Sassari, Italy
[8] Univ Palermo, Biomed Dept Internal & Specialist Med, Nucl Med Unit, Palermo, Italy
[9] Univ Genoa, Dept Hlth Sci DISSAL, IRCCS Osped Policlin San Martino, Nucl Med, Genoa, Italy
[10] Univ Genoa, Dept Hlth Sci DISSAL, Genoa, Italy
[11] Alma Mater Studiorum Bologna Univ, Dept Expt Diagnost & Specialty Med, IRCCS Azienda Osped Univ Bologna, Radiat Oncol, Bologna, Italy
[12] Villa Stuart Private Hosp, Dept Urol, Rome, Italy
[13] Sapienza Univ Rome, Dept Radiol Sci Oncol & Anat Pathol, Rome, Italy
[14] IRCCS Osped Policlin San Martino, Med Oncol Unit 1, Genoa, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17026
引用
收藏
页数：3
相关论文
共 50 条
  • [21] A phase IIa study of radium-223 dichloride (Ra-223) alone or in combination with abiraterone acetate or enzalutamide in metastatic castration-resistant prostate cancer (mCRPC)
    Petrylak, D. P.
    Vaishampayan, U. N.
    Patel, K. R.
    Higano, C. S.
    Albany, C.
    Dawson, N. A.
    Mehlhaff, B. A.
    Quinn, D. I.
    Nordquist, L. T.
    Wagner, V. J.
    Shen, J.
    Trandafir, L.
    Sartor, O.
    ANNALS OF ONCOLOGY, 2019, 30 : 340 - 341
  • [22] A phase Ill trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA.
    Morris, Michael J.
    De Wit, Ronald
    Vogelzang, Nicholas J.
    Tagawa, Scott T.
    Higano, Celestia S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [23] A phase III trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA.
    Morris, Michael J.
    De Wit, Ronald
    Vogelzang, Nicholas J.
    Tagawa, Scott T.
    Higano, Celestia S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [24] A phase III trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA.
    Morris, Michael J.
    De Wit, Ronald
    Vogelzang, Nicholas J.
    Tagawa, Scott T.
    Higano, Celestia S.
    Hamberg, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [25] Symptomatic skeletal event (SSE) dynamics in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223): An interim review of a prospective, noninterventional study (PARABO)
    Poeppel, T.
    Eschmann, S.
    Werner, A.
    Selkinski, I.
    Moellers, M-O.
    Neusser, T.
    Benson, A.
    Kalinovsky, J.
    Palmedo, H.
    ANNALS OF ONCOLOGY, 2018, 29 : 289 - +
  • [26] UTILIZATION OF RADIUM-223 DICHLORIDE (RA-223) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN CANADA: A REAL-WORLD RETROSPECTIVE STUDY
    Lapierre, M.
    Fraelic, A.
    VALUE IN HEALTH, 2016, 19 (03) : A162 - A162
  • [27] Use of bone health agents (BHAs) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) after abiraterone (Abi): An interim review of REASSURE
    Sternberg, C. N.
    Tombal, B.
    Miller, K.
    Saad, F.
    Sartor, O.
    Sade, J. P.
    Logothetis, C.
    Bellmunt, J.
    Dizdarevic, S.
    Harshman, L. C.
    Logue, J.
    Baldari, S.
    Richardson, T.
    Bottomley, D.
    Schostak, M.
    Bayh, I.
    Kalinovsky, J.
    Higano, C.
    ANNALS OF ONCOLOGY, 2018, 29 : 288 - 288
  • [28] Contemporary use of radium-223 (Ra-223) in men with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Feasibility and safety.
    Emamekhoo, Hamid
    Chowdry, Rajasree Pia
    Elson, Paul
    Ledet, Elisa M.
    Martin, Allison
    Cotogno, Patrick
    Beach, Jennifer
    Steinberger, Allie E.
    Allman, Kimberly D.
    Stolten, Michael
    Garcia, Jorge A.
    Sartor, Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [29] A randomized phase 2 study investigating 3 dosing regimens of radium-223 dichloride (Ra-223) in bone metastatic castration-resistant prostate cancer (mCRPC).
    Sternberg, Cora N.
    Saad, Fred
    Graff, Julie Nicole
    Peer, Avivit
    Vaishampayan, Ulka N.
    Leung, Eugene
    Rosenbaum, Eli
    Gurney, Howard
    Epstein, Richard
    Davis, Ian D.
    Wu, Bingyan
    Trandafir, Lucia
    Wagner, Volker Jean
    Hussain, Maha
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [30] Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) sequentially treated with abiraterone acetate (AA) and radium-223 (RA223).
    Caffo, Orazio
    Frantellizzi, Viviana
    Tucci, Marcello
    Galli, Luca
    Monari, Fabio
    Baldari, Sergio
    Masini, Cristina
    Bortolus, Roberto
    Facchini, Gaetano
    Alongi, Pierpaolo
    Zichi, Clizia
    Biasco, Elisa
    Fanti, Stefano
    Pignata, Salvatore
    Filice, Angelina
    Borsatti, Eugenio
    Rossetti, Sabrina
    Spada, Massimiliano
    Cortesi, Enrico
    De Vincentis, Giuseppe
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345